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INTRODUCTION
The basic helix-loop-helix (bHLH) family of transcription
factors plays a key role in the sequence of cell fate decisions
that occurs during differentiation. One group of these proteins
are the EoS genes in Drosophila (Delidakis and Artavanis-
Tsakonas, 1992). EoS genes are expressed after activation of
the Notch pathway that regulates cell fate decision and
boundary formation (Jennings et al., 1994). EoS proteins act
as repressors of transcription and regulate differentiation and
cell fate in such diverse contexts as neurogenesis, sex
determination and imaginal disc formation. In many but not all
cases, the phenotype resulting from EoS overexpression
parallels the phenotype produced by Notch activation (Dawson
et al., 1995; de Celis et al., 1996; Nakao and Campos-Ortega,
1996). 
The vertebrate homologues of EoS have been named Hes,
her and ESR genes in mammals, zebrafish and Xenopus
respectively. These proteins share three highly conserved
features. The basic region of the bHLH domain contains a
characteristic proline residue. C-terminal to the bHLH domain
is a region known as the orange domain, which confers
specificity of function to different family members, enhances
protein-protein interactions between Hes proteins and has a
role in transcriptional repression (Castella et al., 2000; Dawson
et al., 1995; Giebel and Campos-Ortega, 1997; Leimeister et
al., 2000). At the N terminus is a WRPW motif that binds the
transcriptional repressor Groucho and its mammalian
homologues, the TLE proteins (Grbavec and Stifani, 1996;
Paroush et al., 1994). EoS homologues have a wide range of
biological functions in vertebrates, including the regulation of
neural development in response to Notch signalling and somite
formation (Jen et al., 1999; Ohtsuka et al., 1999). 
We are interested in the role of Hes genes in myogenesis.
In Drosophila, the EoS mutant displays increased numbers of
myogenic cells (Corbin et al., 1991). In vitro, overexpression
of Hes1 blocks myogenesis induced by MyoD in 10T1/2 cells
(Sasai et al., 1992). Hes1 transcription is rapidly induced by
Notch activation in C2C12 myoblasts, correlating with a
block in the ability of cells to differentiate in low serum
medium (Jarriault et al., 1998; Kuroda et al., 1999). However,
Hes1 overexpression alone does not block C2C12
differentiation, suggesting that other factors are required in
this system (Shawber et al., 1996). From this data it seemed
likely that other Hes family members might be involved in
regulating myogenesis, in addition to Hes1. By searching the
expressed sequence tag (EST) database, we have identified a
novel Hes cDNA in EST clones derived from skeletal muscle
libraries. This cDNA has been independently identified by
other groups and named Hes6 (Bae et al., 2000; Koyano-
Nakagawa et al., 2000; Pissarra et al., 2000; Vasiliauskas and
Stern, 2000). 
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Hes6 is a basic helix-loop-helix transcription factor
homologous to Drosophila Enhancer of Split (EoS)
proteins. It is known to promote neural differentiation and
to bind to Hes1, a related protein that is part of the Notch
signalling pathway, affecting Hes1-regulated transcription.
We show that Hes6 is expressed in the murine embryonic
myotome and is induced on C2C12 myoblast differentiation
in vitro. Hes6 binds DNA containing the Enhancer of Split
E box (ESE) motif, the preferred binding site of Drosophila
EoS proteins, and represses transcription of an ESE box
reporter. When overexpressed in C2C12 cells, Hes6 impairs
normal differentiation, causing a decrease in the induction
of the cyclin-dependent kinase inhibitor, p21Cip1, and an
increase in the number of cells that can be recruited back
into the cell cycle after differentiation in culture. In
Xenopus embryos, Hes6 is co-expressed with MyoD in early
myogenic development. Microinjection of Hes6 RNA in
vivo in Xenopus embryos results in an expansion of
the myotome, but suppression of terminal muscle
differentiation and disruption of somite formation at the
tailbud stage. Analysis of Hes6 mutants indicates that the
DNA-binding activity of Hes6 is not essential for its
myogenic phenotype, but that protein-protein interactions
are. Thus, we demonstrate a novel role for Hes6 in multiple
stages of muscle formation.
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Hes6 shares the key features of EoS proteins described
above. The bHLH domain contains the conserved proline
residue, the orange domain is present and a WRPW motif is
found at the C terminus. A feature that distinguishes Hes6 from
other EoS homologues is the structure of the loop region of the
bHLH domain, which is four or five amino acids shorter than
that of other Hes proteins (Bae et al., 2000; Koyano-Nakagawa
et al., 2000). Surprisingly, Hes6 does not bind to the E or N
box motifs recognised by other Hes proteins, leading to the
suggestion that it may not bind DNA at all, but rather act by
heteromultimerising with other Hes proteins to modify
transcription. In support of this, Hes6 binds to mouse Hes1 and
XHairy 2A proteins in in vitro assays, and inhibits the
transcriptional repressor activity of Hes1 at an N box reporter
in co-transfection experiments (Bae et al., 2000; Koyano-
Nakagawa et al., 2000).
The function of Hes6 has been investigated in vitro in
explant cultures of retinal precursors, where retroviral
overexpression of Hes6 promotes rod photoreceptor
differentiation at the expense of other cell types (Bae et al.,
2000). In Xenopus, Hes6 overexpression promotes neural
differentiation (Koyano-Nakagawa et al., 2000). Hes6
transcription does not appear to be regulated by Notch
activation in Xenopus embryos (Koyano-Nakagawa et al.,
2000). However, overexpression of the proneural proteins
Xngn1 and Xash3 induces Hes6, and Hes6 is lost in Ngn1
knockout mice, indicating that Hes6 transcription may be
regulated by these proteins in the developing nervous system.
Mice with a homozygous deletion of Hes6 appear
phenotypically normal, suggesting that mouse Hes6 is
functionally redundant. 
Although Hes6 is highly expressed in the developing
myotome, its function in myogenesis has not been investigated
previously (Koyano-Nakagawa et al., 2000; Pissarra et al.,
2000; Vasiliauskas and Stern, 2000). We find that Hes6 binds
to the ESE box motif that is the preferred binding site of
Drosophila EoS proteins. We investigated the effects of Hes6
overexpression in C2C12 myoblasts and found that
differentiation was inhibited, with a substantial reduction in the
proportion of cells undergoing cell cycle withdrawal. In
Xenopus embryos, Hes6 is also found in myogenic precursors.
When overexpressed, it perturbed myogenesis, increasing the
size of the myotome but decreasing the expression of a late
marker of terminal muscle differentiation. In addition, Hes6
overexpression disrupted somite formation. There was no
apparent difference in the phenotype produced by wild-type
Hes6 and a mutant that lacked DNA-binding activity in the in
vitro or in vivo studies. This suggests that Hes6 mediates its
effects by protein-protein interactions, rather than by acting as
a transcription factor.
MATERIALS AND METHODS
Plasmids and cloning
Murine Hes6 was identified by searches of the EST database using
the tBLASTn programme to identify EST clones encoding proteins
homologous to Drosophila EoS proteins. A full-length image clone,
W66929 was found and was completely sequenced. The sequence was
found to be identical to recently reported sequence for Hes6 (Bae et
al., 2000; Koyano-Nakagawa et al., 2000; Pissarra et al., 2000;
Vasiliauskas and Stern, 2000). An EcoRI SacI fragment of murine
Hes6 containing the coding region was subcloned into pGEM-3
(Promega), with and without an N-terminal HIS tag, and into pIRES2-
EGFP (Clontech). A mutant of murine Hes6, Hes6DBM, in which the
basic region amino acids were mutated from VEKKRRARIN to
VKEEEDAEIN was created using a Quikchange mutagenesis kit
(Stratagene). Murine Hes6 and Hes6DBM were also cloned into
pCS2, and into pBabepuro-GFP, a modified pBabepuro vector
containing the internal ribosome entry site and the enhanced green
fluorescent protein (EGFP) cDNA from pIRES2-EGFP (Clontech)
(Morgenstern and Land, 1991).
Xenopus cDNAs encoding wild-type and mutant Hes6 in pCS2
were a gift from Chris Kintner, Salk Institute.
Reporter vectors used were pCOLluc3, comprising the base pairs
–520 to +63 of the collagenase promoter upstream of firefly luciferase
(a gift from Anna-Lisa Montesanti, Oxford, UK) (Angel et al., 1987),
pCOLluc3-ESE, containing two ESE box boxes cloned 5 ¢ of the
collagenase promoter, and pRLTK (Promega), a transfection
efficiency control.
All PCR generated constructs were verified by complete
sequencing, other constructs were sequenced at vector-insert
junctions.
Cell culture
C2C12 cells were obtained from the European Collection of Cell
Cultures, Salisbury, UK. COS and 3T3 cells were obtained from the
American Tissue Culture Collection. GP+E retroviral producer cells
were a gift from Dr F. Watt, Imperial Cancer Research Fund, London,
UK. GP+E, COS7 and 3T3 cells were maintained in DMEM
supplemented with 10% foetal calf serum (FCS; Gibco BRL). C2C12
cells were maintained in growth medium, GM, consisting of DMEM
with 15% FCS. For differentiation experiments, C2C12 cells were
grown to confluence and then transferred to differentiation medium,
(DM), consisting of DMEM plus 2% FCS (Jarriault et al., 1998).
Immunofluorescent staining of C2C12 myoblasts
Primary antibodies used were goat anti-p21Cip1 (C 19, Santa Cruz
Biotechnology), mouse anti-Troponin-T (clone JLT-12, Sigma),
mouse anti-5-bromo-2¢ -deoxyuridine (BrdU, Dako). Secondary Cy3-
conjugated Goat anti-mouse and donkey anti-goat antibodies were
from Jackson ImmunoResearch.
Cells were washed in phosphate buffered saline (PBS), fixed in 1%
paraformaldehyde (for visualising EGFP) or cold methanol (for
immunofluorescence), washed in PBS and blocked in PBS containing
2% serum of the same species as the secondary antibody for 1 hour.
Antibodies were diluted in 2% serum. After mounting in Vectashield
aqueous mountant with DAPI (Vector Laboratories), cells were
photographed on a Zeiss Axiophot II microscope. 
To determine the number of p21Cip1-positive nuclei, DAPI- and
Cy3-stained images were merged using Adobe Photoshop and at least
1000 nuclei from randomly selected fields were counted for each cell
type after 48 hours and 120 hours in DM in each experiment.
BrdU labelling
After differentiation for 5 days in DM, C2C12 myoblasts were
incubated for 20-22 hours in GM containing 50 m M BrdU, washed in
PBS, fixed in cold methanol and then stained for BrdU as described
(Celis and Madsen, 1994). DAPI- and Cy3-stained images were
merged and at least 1000 nuclei from randomly selected fields were
counted for each cell type in each experiment. 
Northern blotting
RNA was isolated from C2C12 cells using RNAzol B. An EcoRI/SacI
fragment of Hes6 cDNA was used as a probe. The myogenin probe
was an EcoRI, NotI fragment of image clone 425649, which was
sequenced to confirm it encoded murine myogenin. A mouse multiple
tissue northern blot was hybridised according to the manufacturer’s
instructions (Clontech).
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In situ hybridisation of mouse embryos
35S-labelled in situ hybridisation was performed on paraffin-wax
embedded sections of mouse embryos by the Imperial Cancer
Research Fund in situ hybridisation service as described (Decimo et
al., 1993). 
Reporter assays
Six-well tissue culture plates (Falcon) were seeded with 105 COS or
3T3 cells on the day before transfection. Expression vector (1.66 m g;
pIRES2-EGFP-b Gal or pIRES2-EGFP–Hes6), 66 ng of Renilla
luciferase control vector (pRLTK) and 0.33 m g Firefly luciferase
reporter vector (pCOLluc3 or pCOLluc3-ESE) were transfected into
each well using Superfect (Qiagen) according to the manufacturer’s
instructions. All transfections were performed in triplicate or
quadruplicate wells. Forty-eight hours after transfection cells were
lysed and analysed for Firefly and Renilla luciferase activity using the
dual luciferase reporter system (Promega).
Electrophoretic mobility shift assays (EMSA)
Wild type or N-terminal His tagged murine Hes6 protein was
generated using a TnT T7 in vitro transcription and translation kit
(Promega). The presence of full-length protein was confirmed by
autoradiography of an 35S-methionine labelled translation performed
in parallel (data not shown).
The following double stranded oligonucleotides were used in
EMSA: ESE box, containing two Enhancer of Split E box (ESE)
motifs (underlined), 5 ¢ GGTGGCACGTGCCATTTGGCACGTGCC-
ATG 3 ¢ ; E box, containing two E boxes (underlined),
5¢ GGACACGTGTTCACGTGACATG 3 ¢ ; N Box, containing two N
boxes (underlined), 5 ¢ ACGCCACGAGCCACAAGGATTG 3¢
(Jennings et al., 1999). Double stranded oligonucleotides were
labelled with 32P by kinase treatment. Labelled oligonucleotide (25
fM) was incubated with 5 m l in vitro translated protein for 45 minutes
on ice in a buffer containing 20 mM Hepes pH 7.4, 50 mM KCl, 2
mM b -mercaptoethanol, 10% glycerol, with 0.05 mg/ml poly(dIdC)
(Amersham Pharmacia Biotech), and 0.5% bovine serum albumin. In
some experiments antibodies were added, either 1 m l of control IgG
(Sigma) or 1 m l of anti-HIS antibody (Sigma).
Retroviral expression of mHes6
GP+E cells were transfected using superfect (Qiagen). After selection
in 2.5 m g/ml puromycin for 7 days, infected GP+E cells were sorted
by flow cytometry to obtain the highest 20% of green fluorescent cells.
Supernatants of these cells were used to infect C2C12 myoblasts, by
incubation of the conditioned medium in the presence of 8 m g/ml
polybrene (Sigma). The infected cells were used in experiments after
7-10 days of puromycin selection. To assess the proportion of cells
expressing EGFP, wild-type C2C12 cells (negative control) and
infected myoblasts were analysed for EGFP fluorescence by flow
cytometry. Cells grown in GM were trypsinised, washed in GM and
in PBS, and then fixed in 1% paraformaldehyde; those with green
channel fluorescence in excess of the wild-type C2C12 cells were
scored as positive.
Xenopus embryos, fixation, b -galactosidase staining and
mRNA injection
Xenopus laevis embryos were obtained by hormone induced laying
and in vitro fertilisation using standard methods. The embryos were
dejellied in 2% cysteine pH 7.8-8.0 then washed and incubated in 0.1 ·
MBS. Embryos were staged according to Nieuwkoop and Faber
(Nieuwkoop and Faber, 1994). Embryo fixation and staining for b -
galactosidase (200-300 pg injected per embryo) was performed as
described (Sive et al., 2000). 
Capped RNAs were synthesised in vitro from nuc- b -gal (Chitnis et
al., 1995) XHes6, XHes6DBM, XHes6 D WRPW (Koyano-Nakagawa
et al., 2000), murine Hes6 and Hes6DBM using the SP6 Message
Machine kit (Ambion). Where appropriate, embryos were injected in
0.2· MBS supplemented with 6% Ficoll and transferred to 0.1 · MBS
after gastrulation. 
Xenopus embryo in situ hybridisation and antibody
staining
Whole mount in situ hybridisation was performed as described
(Shimamura et al., 1994). Linearised Bluescript plasmids from
Nb tubulin (BamHI/T3), XMyoD (HindIII/T7) and muscle actin
(HindIII/T7) were used to generate digoxigenin-11-UTP-labeled
(Boehringer Mannheim) antisense RNA probes from the indicated
polymerases. BM Purple (Boehringer Mannheim) was used as a
substrate. 
Whole-mount antibody staining was performed as described in the
Cold Spring Harbor Xenopus Laboratory Manual (2000) using the
12/101 antibody (obtained from DSHB) (Kintner and Brockes, 1984),
at 1:500, and an alkaline phosphatase-conjugated goat anti-mouse
antibody (Sigma) at 1:1000. Antibody staining was developed using
NBT and BCIP as colour substrates. 
For histological analysis, embryos were embedded in paraffin and
sectioned at 10 m m. Monoclonal anti- a -sarcomeric actin clone (5C5)
(Sigma) applied at 1:400 for 2 hours at room temperature was
recognised with a secondary goat anti-mouse IgM Cy3 (1:300)
(Jackson Immunoresearch). 
Sections were analysed using images captured with Zeiss
Axiovision 2.05 (Imaging Associates, Thame, UK) and quantitation
was performed using Openlab 2.2.1 software (Improvision, Viscount
Centre II, Coventry, UK). Areas of muscle-specific staining were
calculated by outlining the region of staining on the computer and
determining the area within the trace. The area of the injected side
was divided by the area of the uninjected side to yield a ratio. Sections
throughout the region of the embryo expressing b -gal were randomly
selected (from 10 sections per embryo in four embryos in the
experiment shown) in order to reduce artifactual or biasing
differences. 
RESULTS
Expression of Hes6 in developing mouse muscle
Hes6 was cloned by searches of the mouse expressed sequence
tag database for cDNAs encoding homologues of the
Drosophila Enhancer of Split proteins that are expressed in
muscle-derived libraries. We analysed the expression of Hes6
mRNA in mouse embryos using in situ hybridisation.
Expression was detected in the developing brain and retina
(data not shown), and in the developing somites in day 13 p.c.
embryos as previously reported (Fig. 1A,B) (Koyano-
Nakagawa et al., 2000; Pissarra et al., 2000; Vasiliauskas and
Stern, 2000). In addition, we saw expression in developing
skeletal muscle, both in the limbs and in the axial musculature,
such as the diaphragm and intervertebral muscles in day 16 p.c.
embryos (Fig. 1C,D and data not shown). However Hes6
mRNA was undetectable by in situ hybridisation in adult
skeletal muscle (Fig. 1E,F). Consistent with this observation,
analysis of adult mouse tissue by northern blotting revealed
Hes6 mRNA in heart, liver, kidney and lung but not skeletal
muscle (Fig. 1G). We went on to see if Hes6 was expressed in
the C2C12 mouse myoblast cell line when induced to
differentiate by serum deprivation. In cells in high serum
growth medium (GM), Hes6 mRNA was undetectable (Fig.
1H). However, when C2C12 cells were induced to differentiate
in low serum differentiation medium (DM), transcription of
Hes6 was increased. The increase in Hes6 mRNA paralleled
the induction of myogenin transcription, confirming induction
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of differentiation (Andres and Walsh, 1996). Thus, Hes6 is
expressed during muscle differentiation in vivo and in vitro,
but expression is downregulated in adult muscle.
Hes6 binds to an Enhancer of Split E box and
mediates transcriptional repression
Hes6 has been shown to act indirectly by binding other orange
domain-containing proteins, rather than by acting as a DNA-
binding transcription factor (Bae et al., 2000; Koyano-
Nakagawa et al., 2000). As reported previously, we found that
Hes6 did not bind to the E and N box motifs recognised by
other Hes proteins in an electrophoretic mobility shift assay
(EMSA, data not shown) (Bae et al., 2000; Koyano-Nakagawa
et al., 2000). However, we also tested binding to the Enhancer
of Split E box (ESE box), a 12 nucleotide motif containing an
E box identified by random oligonucleotide selection
experiments with Drosophila EoS proteins (Jennings et al.,
1999). Using in vitro translated protein, both wild-type and
epitope-tagged Hes6 were found to bind an ESE box
containing oligonucleotide in EMSA (Fig. 2A; data
not shown). Binding was competed out by unlabelled
oligonucleotide and a supershift of epitope tagged
murine Hes6 demonstrated the specificity of the
interaction. An excess of unlabelled E or N box-
containing oligonucleotides had no effect on the
binding of murine Hes6 to an ESE box, even in 200-
fold molar excess of competitor (Fig. 2B). This
confirms that the affinity of Hes6 was far higher for
the ESE box than an E box or an N box. 
Other Hes proteins show transcriptional repressor
activity in transient transfection assays (Bessho et al.,
2001; Sasai et al., 1992). We tested the ability of Hes6
to alter transcription of a model reporter containing ESE
repeats. A fragment of the collagenase promoter (COL)
that contains no E, N or ESE motifs was used for these
experiments (Angel et al., 1987). When a control
construct consisting of the COL promoter driving
expression of luciferase was transfected into COS cells
with Hes6 or b -galactosidase (b -gal)-encoding expression
plasmids, there was no difference in transcription as assessed by
luciferase activity (Fig. 2C). However, when two ESE box motifs
were introduced 5¢ to the COL promoter, there was a decrease
in luciferase activity on transfection of murine Hes6 compared
with b -gal in both COS and 3T3 cells (Fig. 2C; data not shown).
The ratios in luciferase activity, Hes6:b -gal, in COS and 3T3
cells were 0.57:1 and 0.65:1 (means of four and three
experiments, respectively, P=0.010 and P=0.0041, respectively,
by two-tailed paired t-test). These data indicate that Hes6
represses transcription at a model promoter containing ESE
boxes. The degree of transcriptional inhibition seen with Hes6
is similar to that described for other Hes family members such
as Hes1 in similar reporter assays (Bae et al., 2000).
Effects of Hes6 overexpression on C2C12 myoblast
differentiation in vitro
The dynamic expression of Hes6 in mouse muscle and the
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Fig. 1. Hes6 transcription is detectable in developing
muscle in mouse embryos and C2C12 myoblasts in culture.
35S-labelled in situ hybridisation for Hes6 mRNA on
parasaggital sections of mouse embryos. (A,B) Day 13 p.c.
embryo, Hes6 mRNA is present in the developing somites.
(C,D) Day 16 p.c. embryo. Hes6 mRNA is expressed in the
developing muscles in the forelimb; h, humerus.
(E,F) Skeletal muscle (panniculus carnosus) from an adult
mouse. Hes6 mRNA is undetectable. (G) Northern blot
analysis of Hes6 expression in adult mouse tissues,
compared with a g actin control probe that also reacts with
b actin. The difference in the actin hybridisation in the
heart and skeletal muscle lanes reflects tissue specific
differences in the levels of g and b actin. Each lane was
loaded with 2 m g of mRNA. Hes6 mRNA runs at 1.4 kb.
(H) Hes6 transcription during C2C12 myoblast
differentiation in vitro. C2C12 myoblasts were placed into
differentiation medium for 0-4 days. RNA was isolated and
analysed by northern blot. Each lane was loaded with 20 m g
total RNA. The blot was also probed for myogenin, to
confirm induction of differentiation and stained with
Methylene Blue (Me blue) to reveal 18 S RNA. Result
shown is typical of three independent experiments.
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induction of Hes6 expression on C2C12 differentiation
suggested it might have a role in myogenesis. We set out to
determine the effect of overexpression of mouse Hes6 (murine
Hes6) on C2C12 myoblast differentiation in vitro. C2C12
myoblast differentiation follows an ordered sequence of
molecular and cellular events. Myoblasts withdraw from the
cell cycle coincident with induction of the cyclin-dependent
kinase inhibitor (CDKI) p21Cip1 (Andres and Walsh, 1996).
Subsequently, post-mitotic myoblasts undergo fusion to form
myotubes that express terminal differentiation markers such as
Troponin-T (Andres and Walsh, 1996).
A retroviral vector (pBabepuro) with puromycin selection
was used to introduce Hes6 constructs to minimise the amount
of cell culture required after transduction (Fig. 3A)
(Morgenstern and Land, 1991). This approach avoids
prolonged culture of C2C12 cells that can cause them to lose
the ability to differentiate (Tachibana and Hemler, 1999). In
each experiment, all cells were matched for passage number.
A bicistronic EGFP vector was used to enable retrovirally
derived protein expression in infected cells to be followed
during differentiation without having to use an epitope tagged
form of Hes6 (Fig. 3A). After selection in puromycin for 1-2
weeks, the proportion of cells expressing EFGP was assessed
by flow cytometry. The proportion of cells expressing
detectable levels of EGFP was 89% for b -gal, 95% for murine
Hes6 and 94% for murine Hes6DBM (data not shown). To test
if the DNA-binding activity of Hes6 was required for any
changes in myogenic differentiation consequent on Hes6
overexpression, we mutated the DNA-binding site of murine
Hes6 as shown in Table 1, to create Hes6DBM. As a control
we used a virus encoding b -gal.
We found no apparent change in C2C12 myoblasts after
infection with the Hes6 or Hes6DBM viruses compared with
the control b -gal virus while the cells were maintained in GM
(data not shown). Levels of GFP expression, assessed by flow
cytometry, were similar with each virus (data not shown).
However, when the cells were induced to differentiate by
culture in DM for 5 days, a marked difference in cellular
morphology was seen comparing either the Hes6 or Hes6DBM
transduced cells with the control cells (Fig. 3B-D). Myotubes
formed in cells transfected with all three constructs, but
appeared elongated and narrowed with Hes6 or Hes6DBM
compared with the b -gal control. No difference was seen
comparing the morphology of murine Hes6 with murine
Hes6DBM overexpressing cells.
Immunofluorescent staining revealed that Troponin-T-
expressing myotubes were present in differentiated mouse
Hes6 or mouse Hes6DBM overexpressing cultures as well as
b -gal controls, though the number of nuclei per Troponin-T
positive cell was reduced in the cells expressing the Hes6
constructs (Fig. 3E-G). The proportion of nuclei in Troponin-
T-positive cells was typically 50% lower in murine Hes6 and
murine Hes6 cultures than in b -gal control cultures (Fig. 4A).
The ability of 20% of cells to fuse to form myotubes despite
Fig. 2. Hes6 protein binds to an Enhancer of Split E (ESE) box and
represses transcription at an ESE box containing promoter. EMSA of
Hes6. In vitro translated protein was incubated with the
oligonucleotides shown, as described in the Materials and Methods.
(A) In vitro translation reactions containing either no DNA (left hand
lane) or cDNA encoding Hes6 protein with an N terminal His Tag
(remaining lanes) were incubated with a 32P-labelled ESE box
containing oligonucleotide. The binding reactions were carried out in
the presence of unlabelled ESE box containing oligonucleotide
present in 5-, 50- and 200-fold excess in the lanes shown. IgG
indicates binding reaction carried out in the presence of control IgG;
a HIS, binding reaction in the presence of an anti-HIS tag antibody.
(B) In vitro translations with no DNA or Hes6 cDNA were incubated
with a 32P-labelled ESE box oligonucleotide, as in A. Unlabelled E
box and N box competitor oligonucleotides, present in 5-, 50- and
200-fold excess were added to the reaction as shown. (C) COS cells
were transiently transfected with pIRES2-EGFP plasmids with
inserts encoding b -galactosidase or mouse Hes6, with a reporter
vector consisting of a collagenase promoter driving expression of
firefly luciferase (pCOLluc3) or pCOLluc3 with 2 ESE box motifs
cloned immediately 5¢ of the collagenase promoter (pCOLluc3-ESE).
A renilla luciferase reporter (pRL-TK) was used as a control for
transfection efficiency. The values shown represent the means of four
independent experiments, each performed in triplicate or
quadruplicate wells, normalised to the pIRES b -gal + pCOLluc3-
ESE control. Error bars show s.e.m. *P=0.010 using a two-tailed
paired t-test, comparing Hes6 with b -gal control, when each was co-
transfected with pCOLLuc3-ESE reporter.
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overexpression of Hes6 may reflect the heterogeneity of cell
types in the C2C12 cell line and differences in the levels of
Hes6 expression in the polyclonal population (Yoshida et al.,
1998).
We hypothesised that the reduction in the number of cells
undergoing fusion to form Troponin-T positive myotubes may
reflect either a decrease in the number of myoblasts undergoing
cell cycle withdrawal or a block in the process of cell fusion
by post-mitotic myoblasts. To investigate if there was a
decrease in the number of cells undergoing cell cycle
withdrawal, cultures were examined for expression of the
p21Cip1 protein (Andres and Walsh, 1996). In western blots, the
anti-p21Cip1 antibody used recognised a protein corresponding
in size to p21Cip1 in b -gal, murine Hes6 and Hes6DBM-
infected cells cultured in DM (data not shown). For cultures in
GM, the proportion of p21Cip1-positive nuclei was under 1%
(data not shown). Control b -gal cultures significantly induced
expression of p21Cip1 within 48 hours of being placed in DM.
By contrast, p21Cip1 induction was markedly inhibited in cells
overexpressing murine Hes6 or Hes6DBM (Fig. 3H-J; Fig.
4B). The induction of p21Cip1 was not merely delayed, as the
difference in expression between the murine Hes6 or
Hes6DBM overexpressing cells and controls was maintained
in cultures examined after 5 days in DM (Fig. 4B). There was
no significant difference between Hes6- and Hes6DBM-
expressing cells, suggesting that the binding of DNA by Hes6
is not required to inhibit induction of p21Cip1. 
Multiple CDKIs are active in myogenic differentiation in
addition to p21Cip1 (Franklin and Xiong, 1996; Zabludoff et al.,
1998). We therefore needed to confirm that the cells that were
p21Cip1 negative were able to re-enter the cell cycle and were
not post-mitotic because of the activity of other CDKIs. This
was investigated by BrdU labelling of differentiated cultures.
After 5 days in DM, cultures were transferred into GM
containing BrdU for 20-22 hours (Andres and Walsh, 1996).
The number of BrdU-positive cells was then analysed by
immunofluorescence (Fig. 3K-M; Fig. 4C). The proportion of
BrdU-positive nuclei was increased in cells expressing murine
Hes6 or Hes6DBM compared with the control cells (Fig. 4C).
In four experiments, the mean ratio of BrdU-positive cells
(murine Hes6:b gal) was 1.45:1 (±0.07, s.e.m.) for murine Hes6
and 1.42:1 (±0.07, s.e.m.) for Hes6DBM, demonstrating no
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Fig. 3. Analysis of effects of overexpression of murine Hes6
and Hes6DBM on C2C12 myoblast differentiation. C2C12
myoblasts were infected with bicistronic retroviral vectors
encoding b galactosidase (b -gal), murine Hes6 (mHes6) or
Hes6DBM (mHes6DBM) and GFP as described in the
Materials and Methods. Cells were cultured for 5 days in DM
and then analysed by immunofluorescence. (A) Structure of
retroviral vector. A bicistonic retroviral vector was used.
Transcription of RNA encoding the insert, an internal ribosome
entry site (IRES) and cDNA encoding EGFP is driven by the 5 ¢
long terminal repeats (LTR). Translation of the bicistronic RNA
produces two proteins, the inserted protein and EGFP.
Expression of the puromycin resistance gene (puro) is driven
by the SV40 viral promoter (SV40). (B-D) EGFP expression.
Unstained cells were examined for EGFP fluorescence to
confirm translation of the retrovirally expressed bicistronic
RNA. There was no apparent difference in the level of EGFP
expression, but in cells overexpressing Hes6 or Hes6DBM, the
myotubes were elongated and narrower than b -gal-expressing
cells. Appearances shown are typical of five independent
experiments. (E-G) Troponin-T expression. Cells were stained
with an anti-Troponin-T antibody. Myotubes expressed
Troponin-T, a marker of terminal differentiation. The different
morphology of myotubes in murine Hes6 and Hes6DBM
cultures is seen; the number of nuclei per myotube is lower in
murine Hes6 and Hes6DBM transduced cells compared with b -
gal expressing cells. Appearances shown are typical of five
independent experiments. (H-J) p21Cip1 expression. Cells were
stained with an anti-p21Cip1 antibody, disclosed with a Cy3-
conjugated secondary antibody. Nuclei were stained with
DAPI. Rows of p21Cip1-positive nuclei correspond to
multinucleate myotubes. Fewer p21Cip1-positive nuclei occur in
the murine Hes6- and HES6DBM-expressing cells (see Fig. 4).
(K-M) BrdU labelling to detect cells capable of re-entering into
the cell cycle. To determine the proportion of cells in each
culture that had undergone irreversible cell cycle withdrawal,
cells were exposed to GM containing 50 m M BrdU for 20-22 hours after 5 days in DM. Nuclei were then stained with an anti-BrdU antibody
and disclosed with a Cy3-conjugated secondary antibody. Nuclei were then stained with DAPI. More BrdU-positive cells are found in the
murine Hes6- and Hes6DBM-expressing cells (see Fig. 4).
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difference between murine Hes6 and Hes6DBM. These
observations indicate that the lack of large multinucleate
myotubes in cultures overexpressing murine Hes6 or
Hes6DBM is due, at least in part, to inhibition of myoblast
terminal differentiation at or before the induction of p21Cip1,
resulting in a decrease in the number of post-mitotic myoblasts.
We have shown that Hes6 is expressed in the embryonic
mouse myotome but expression is lost in adult muscle. In
mouse myoblast cultures, sustained high level expression of
Hes6 resulted in a block in terminal differentiation. These
data support the hypothesis that downregulation of Hes6
expression is required for terminal muscle differentiation.
Hes6 expression in Xenopus embryos
The in vitro data and expression pattern of Hes6 in the
embryonic myotome of mice supported the hypothesis that
Hes6 has a role in myogenic differentiation. Hes6 is highly
conserved between mouse and Xenopus, suggesting Xenopus
embryos as an appropriate system to test the effects of Hes6
overexpression on myogenesis in vivo. We examined the
spatial expression pattern of XHes6 in early gastrula and
tailbud stage embryos using whole-mount in situ hybridisation.
At early gastrula stages, XHes6 was expressed in a ring around
the closing blastopore but was excluded from the most dorsal
region (Fig. 5A). This expression pattern matches that seen for
MyoD which is expressed in involuting mesoderm that will
mostly go on to differentiate into muscle (Fig. 5B) (Frank and
Harland, 1991). However expression of XHes6 is markedly
different from MyoD at the tailbud stage. While MyoD
expression is maintained in the myotome, XHes6 expression is
absent except for two to three chevron stripes immediately
anterior to the tailbud and the tailbud itself (Fig. 5C,D)
(Koyano-Nakagawa et al., 2000). The absence of XHes6
staining in the bulk of the differentiated myotome at tailbud
stages is consistent with the model suggested by our in vitro
experiments, that Hes6 expression must be downregulated to
allow terminal differentiation to proceed. Moreover, expression
in chevrons anterior to the tailbud and in the tailbud itself
is very reminiscent of the expression patterns of XDelta2,
Thylacine-1, ESR-4 and ESR-5 which have all been implicated
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Fig. 4. Overexpression of murine Hes6 (mHes6) and Hes6DBM
(mHes6DBM) in C2C12 myoblasts decreases the number of cells
undergoing irreversible cell cycle withdrawal. (A) C2C12 cells were
cultured in DM for 120 hours, fixed and stained for
immunofluorescent analysis of the proportion of nuclei in Troponin-
T-positive cells, as shown in Fig. 3. Results of a typical experiment
are shown. The mean of five random fields containing a total of at
least 600 nuclei is shown, error bars indicate s.d. *P=0.004,
**P=0.001, comparing murine Hes6 and Hes6DBM, respectively,
with b -gal control using a two-tailed unpaired t-test. There was no
significant difference between murine Hes6 and Hes6DBM. (B)
C2C12 cells were cultured in DM for 48 or 120 hours, fixed and
stained for immunofluorescent analysis of the proportion of p21Cip1-
positive nuclei as shown in Fig. 3. The mean proportion of p21Cip1-
positive nuclei expressed as a percentage of the total number nuclei
in three independent experiments is shown. At least 1000 nuclei for
each cell type were counted from random microscope fields at each
time point in each experiment. Error bars show s.e.m. *P=0.037,
**P=0.040, comparing murine Hes6 with b -gal control using a two-
tailed paired t-test at 48 and 120 hours, respectively. +P=0.013,
++P=0.009, comparing murine Hes6DBM with b -gal control using a
two-tailed paired t-test at 48 and 120 hours, respectively. There was
no significant difference between the percentage of p21Cip1-positive
cells for murine Hes6 and Hes6DBM at either time point. (C) Cells
were cultured in DM for 5 days and then placed in GM containing
50 m M BrdU for 20-22 hours. Cells were then fixed and stained for
BrdU to determine the proportion of BrdU-positive nuclei as shown
in Fig. 3. The mean proportion of BrdU-positive nuclei expressed as
a percentage of the total number nuclei in three independent
experiments is shown. At least 1000 nuclei for each cell type were
counted from random microscope fields at each time point in each
experiment. Error bars show s.e.m. *P=0.008, **P=0.015,
comparing murine Hes6 and Hes6DBM, respectively, with b -gal
control using a two-tailed paired t-test. There was no significant
difference between murine Hes6 and Hes6DBM.
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in the process of somitogenesis (Jen et al., 1999; Jen et al.,
1997; Sparrow et al., 1998).
Hes6 overexpression enlarges the Xenopus
myotome 
To investigate the effect of Hes6 overexpression in vivo, we
prepared RNA and injected it into one cell of two-cell stage
embryos, with the lineage tracer b -gal. This procedure
provides a useful internal control, as the first cleavage, which
bisects the embryo into left and right, results in expression of
message on only one side of the embryo. Three constructs were
used to investigate the effect of XHes6 in vivo: (1) full-length
wild-type XHes6, (2) a DNA-binding mutant, XHes6DBM,
and (3) a mutant with a four amino acid deletion that disrupts
binding to Groucho homologues (XHes6 D WRPW) (see Table
1) (Koyano-Nakagawa et al., 2000). To confirm the activity of
these constructs, embryos were assayed for the formation of
primary neurones by staining for neural b tubulin (Nb tub) at
the neural plate stage. All three constructs significantly
upregulated N b tub expression as previously reported (Fig. 6A;
Table 2) (Koyano-Nakagawa et al., 2000). 
To investigate whether XHes6 affected myotome formation
in vivo, in situ hybridisation for MyoD and muscle actin (MA)
mRNA were performed on overexpressing embryos at neural
plate stages. While XHes6 and XHes6DBM both considerably
enlarged the area of MyoD (Fig. 6D,E) and MA (Fig. 6G,H)
expression, the XHes6 D WRPW mutant had very little effect on
either MyoD or MA transcripts (Fig. 6F,H; Table 2). 
To quantify the effects of XHes6, XHes6DBM and
XHes6D WRPW on myotome size, embryos were injected with
synthetic message into one cell at the two-cell stage, fixed at stage
22, transversely sectioned and stained for expression of the early
muscle marker, muscle actin (Fig. 7A-C). The cross-sectional
area staining for muscle actin was calculated to give a measure
of the size of the myotome. Three independent experiments
yielded similar results; the results from one typical experiment
are shown in Fig. 7D. Injection of wild-type XHes6 led to
significant expansion of the size of the myotome on the injected
versus the uninjected side (Fig. 7A,J). Interestingly, XHes6DBM
also led to a significant increase in the size of the myotome,
indicating that DNA binding is not essential for this effect
(Fig. 7B,J). RNA made from the murine Hes6 and Hes6DBM
constructs used in the in vitro experiments, also produced
myotome expansion on overexpression in Xenopus (data not
shown). However, overexpression of the XHes6Hes6D WRPW
mutant did not lead to expansion of the myotome, indicating that
protein-protein interactions mediated by the WRPW domain may
be important in mediating myotome expansion (Fig. 7C,J). With
all constructs, there were no significant changes in the size of the
neural tube or the morphology of the epidermis, indicating the
effects seen were specific to the myotome. 
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Table 1. Hes6 constructs
Hes6 contains a basic helix-loop-helix domain (bHLH), an orange domain
and a terminal WRPW motif, which binds to the transcriptional repressor
Groucho and its homologues. In mouse Hes6DBM, the basic region of the
bHLH domain was mutated as described in the Materials and Methods.
Xenopus Hes6 and XHes6DBM constructs have been described previously
(Koyano-Nakagawa et al., 2000). The amino acid sequence of the
corresponding sequences of the basic domain in the normal and mutated
constructs is shown. The XHes6 D WRPW construct lacks the terminal WRPW
motif. 
Construct Structure Basic region
Murine Hes6 VEKKRRARIN
XHes6 VEKRRRARIN
Murine Hes6DBM VKEEEDAEIN
XHes6DBM VREREEADID
XHes6 D WRPW VEKRRRARIN
bHLH ORANGE WRPW
bHLH ORANGE WRPW
bHLH ORANGE WRPW
bHLH ORANGE
bHLH ORANGE WRPW
Table 2. Effects of XHes6 and mutants on expression of markers of neural and myogenic differentiation assessed by
whole-mount in situ hybridisation
Nb tub MyoD MA
Injected constructs Increase No change Increase No change Increase No change
XHes6 41/66 (62%) 25/66 (38%) 48/62 (77%) 14/62 (23%) 32/52 (62%) 20/52 (38%)
XHes6DBM 43/62 (69%) 19/62 (31%) 35/52 (67%) 17/52 (33%) 38/53 (72%) 15/53 (28%)
XHes6D WRPW 31/69 (45%) 38/69 (55%) 5/38 (13%) 33/38 (87%) 9/51 (18%) 42/51 (82%)
Fig. 5. XHes6 is expressed in the presomitic mesoderm and somitic
chevrons. Embryos were analysed by whole-mount in situ
hybridisation at early gastrula stage (stage 10.5) (A,C) and tailbud
stage (stage 22) (B,D) for expression of MyoD (A,B) and Hes6
(C,D). Both MyoD and Hes6 are found in a ring of prospective
mesoderm around the dorsal pore at stage 10.5 (A,C, respectively).
At stage 22, MyoD is restricted to myotome but is expressed
uniformly throughout (B). Hes6 is found in the eye, brain (asterisk),
neural tube, tailbud domain (TBD) and in two to three chevrons
anterior to the TBD (arrows, D). 
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To confirm that the expanded myotome contained more
cells, we counted the number of nuclei in longitudinal sections
of the myotome double stained for nuclei and MA. At least
2500 nuclei were counted on nine or ten unselected sections
of two typical embryos for each construct, from the same
experiment as shown in Fig. 7. The ratio of
cell number (injected/uninjected) was 3.3:1
(±0.46) for XHes6, 2.3:1 (±0.17) for
XHes6DBM and 1.15:1 (±0.04) for
XHes6D WRPW. All these differences were
statistically significant (P<0.0011 by two-
tailed t-test). Thus, XHes6 and XHes6DBM
both cause a substantial increase in cell
number within the myotome, but
XHes6D WRPW has a minimal effect. 
XHes6 overexpression inhibits terminal myogenic
differentiation
Finally, our experiments with C2C12 cells have shown that
Fig. 6. XHes6 and XHes6DBM increase myotome
size. Embryos were injected with 2 ng of XHes6
(A,D,G), XHes6DBM (B,E,H) or XHes6 D WRPW
(C,F,I) along with b -gal (light blue, injected side
to left) and analysed at the neural plate stage for
Nb Tub (A-C), MyoD (D-F) or a -sarcomeric actin
(MA) (G-I) expression by whole-mount in situ
hybridisation (purple). Overexpression of all three
constructs upregulated N b Tub expression (A-C),
while only XHes6 (D,G) and XHes6DBM (E,H)
upregulated the muscle markers MyoD and MA. 
Fig. 7. XHes6 and XHes6DBM upregulate myogenesis and disrupt somitogenesis. Embryos were injected in one of two cells with 2 ng of
(A,D,E) XHes6, (B,F,G) XHes6DBM or (C,H,I) XHes6 D WRPW along with nuclear b -gal. At stage 22, the embryos were fixed and
transversely (A-C) or longitudinally (D-I) sectioned and analysed for expression of MA (red); nuclei are stained with Hoechst (blue).
Transverse sections are oriented with injected side to the left. Longitudinal sections are arranged with anterior towards the left and the injected
side upwards. Broken white lines indicate the outlines of the embryo, the neural tube and the notochord. Quantitative image analysis was
performed and the ratio of MA-expressing areas on injected and uninjected sides analysed as described in the Materials and Methods; results
are shown in J. The error bars indicate the s.e.m. P values with a two-tailed t test, comparing mean ratios on injected and uninjected sides, were
0.017 for XHes6, 0.004 for XHes6DBM and 0.33 (not significant) for XHes6 D WRPW. Both XHes6 and XHes6DBM cause complete
disruption of somitogenesis (100% of embryos disrupted, n=26, 25 respectively), while XHes6 D WRPW has a minimal effect (10% of embryos
disrupted, n=20). In each embryo, the b -gal tracer was distributed both in the mesoderm and the ectoderm (data not shown)
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overexpression of XHes6 can actively impede terminal
differentiation of muscle cells. To see if overexpression of
XHes6 has this effect in vivo, RNAs were injected into one cell
of two-cell stage embryos along with the tracer b -gal. Embryos
were allowed to develop until stage 22, fixed and stained
with the antibody 12/101, a marker of terminal muscle
differentiation (Kintner and Brockes, 1984). Strikingly, while
the undifferentiated myotome was expanded in embryos
injected with both XHes6 and XHes6DBM, the area and
intensity of muscle staining for the 12/101 antibody on the
injected compared to the uninjected side was decreased in 63%
(19/30) of embryos overexpressing XHes6 (Fig. 8A,B). This
indicated an inhibition of terminal differentiation in the muscle
on the injected side. Similar decreased staining was seen with
the XHes6DBM construct where 89% (17/19) of embryos
showed decreased 12/101 staining (Fig. 8C,D). By contrast,
12/101 staining was only decreased in 10% (4/41) embryos
injected with the D WRPW construct. These results indicate
that overexpression of XHes6 or a XHes6 DNA-binding
mutant can inhibit terminal muscle differentiation in vivo,
while a mutant lacking the WRPW domain cannot. In addition,
gross observation of the 12/101 stained embryos indicated that
the chevronated pattern, indicative of normal somite formation,
was lost in 100% of embryos following both XHes6 and
XHes6DBM overexpression (30/30 and 19/19 embryos,
respectively). By contrast, very little difference was observable
on overexpression of XHes6 D WRPW; only 10% (4/41) of
embryos had disruption of the staining pattern (Fig. 8E-F).
These observations, raised the possibility that Hes6 was
affecting somitogenesis.
XHes6 overexpression disrupts somitogenesis 
Somitogenesis is a complex process whereby blocks of
presomitic mesoderm, which originally lie randomly, align
nuclei, segment and rotate through 90 ° so that the individual
cells of the somite lie in parallel with the long axis of the
embryo (Hamilton, 1969). We have investigated whether
overexpression of XHes6 and its mutant derivatives disrupt this
process. RNAs were again injected unilaterally into one cell of
two-cell stage embryos and the embryos allowed to develop to
tailbud stage. Embryos were sectioned longitudinally and
stained with an anti-MA antibody to reveal somite morphology
and Hoechst to reveal the nuclei. As well as resulting in a
substantial increase in myotome size, as discussed above,
overexpression of wild-type XHes6 also dramatically disrupted
somitogenesis. Actin staining, which allows visualisation of
gross myotomal morphology, revealed that individual somites
had failed to segregate and essentially no intersomitic
boundaries were visible (Fig. 7E). Moreover, Hoechst staining
in the myotome revealed a failure of nuclei to line up or rotate
(Fig. 7D). Similar disruption of somite morphology is seen on
overexpression of XHes6DBM (Fig. 7F,G). By contrast, the
somites formed essentially normally in XHes6 D WRPW-
injected embryos, indicating that protein-protein interactions
involving the WRPW region were important for the disrupted
somite phenotype of XHes6 (Fig. 7H,I). 
DISCUSSION
We have presented evidence that Hes6 may have a role in
regulating myogenic differentiation and somite formation.
Hes6 is expressed in myogenic cells in vitro and in the
embryonic myotome in mouse and Xenopus. Overexpression
of Hes6 inhibits the terminal differentiation of C2C12
myoblasts, resulting in a decrease in the number of cells
withdrawn from the cell cycle in differentiated cultures. Hes6
overexpression in Xenopus results in a complex phenotype,
with an increase in size of the myotome, a decrease in terminal
differentiation and a failure of somitogenesis. By using mutant
forms of Hes6 we have demonstrated that the DNA-binding
activity of the protein is not required to produce these
phenotypes in myoblasts in culture or in Xenopus embryos.
Function of Hes6 protein
As previously reported, Hes6 shows no affinity for E or N box
containing oligonucleotides in EMSA assays (data not shown)
(Bae et al., 2000; Koyano-Nakagawa et al., 2000). However, it
does bind to the same ESE box as Drosophila EoS proteins and
represses transcription at an ESE box-containing reporter
(Jennings et al., 1999). Thus, Hes6 exhibits the properties of a
negative regulator of transcription in in vitro reporter assays,
like other Hes proteins, but the divergent structure of the DNA-
binding domain of Hes6 confers different DNA-binding
properties (Bessho et al., 2001; Sasai et al., 1992). However,
the identical phenotypes seen with wild-type and DBM forms
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Fig. 8. XHes6 and XHes6DBM inhibit terminal myogenic
differentiation. Embryos were injected in one of two cells with 2 ng
of (A,B) XHes6, (C,D) XHes6DBM or (E,F) XHes6 D WRPW with
b -gal (light blue) and analysed at stage 22 for 12/101 expression
(purple) by whole-mount antibody staining. XHes6 and XHes6DBM
both decrease the area, intensity and pattern of 12/101 expression
(compare A,C with B,D). However, XHes6 D WRPW has little effect
on the expression of this terminal myogenic differentiation marker
(E,F). 
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of Hes6 in vitro and in vivo suggest that DNA binding by Hes6
is not required for its roles in myogenesis or somitogenesis. 
The XHes6 D WRPW mutant has a minimal effect on the size
of the myotome, the expression of late markers of terminal
muscle differentiation, and somitogenesis. This finding
contrasts with the effect of this mutant on neurogenesis, where
as shown here and reported previously it produces an increase
in the proportion of tubulin-positive cells in about 50% of
embryos (Fig. 6C; Table 2) (Koyano-Nakagawa et al., 2000).
This suggests that the effects of XHes6 and XHes6DBM
overexpression on myogenesis and somite formation require
the recruitment of Groucho homologues or other proteins via
the WRPW domain, whereas the neural phenotype does not.
This is consistent with Hes6 having a role as a non-DNA-
binding repressor of transcription in myogenic cells, although
a quantitative difference in the effect of the WRPW mutant on
muscle and nerve differentiation cannot be excluded.
The role of Hes6 in myogenesis in vitro
Overexpression of murine Hes6 or murine Hes6DBM in
C2C12 myoblasts results in a decreased number of nuclei per
myotube, which is likely to reflect a reduction in the number
of cells expressing p21Cip1 and undergoing irreversible cell
cycle withdrawal. It is interesting to compare the results of
expression of full-length Hes6 in C2C12 cells with recently
reported data on the function of a truncated form of Hes6
(Hes6T), which lacks the first 16 amino acids of full-length
Hes6 (Gao et al., 2001). In contrast to full-length Hes6, Hes6T
synergises with Hes1 in repression of an N box reporter, and
promotes C2C12 terminal differentiation (Bae et al., 2000; Gao
et al., 2001). This indicates an important function for the N
terminus of the wild-type protein.
Protein-protein interactions seem to mediate the effect of
Hes6 on C2C12 cells as Hes6DBM produces the same
inhibition of differentiation as the wild-type protein. A
candidate for such an interaction is Hes1, a Notch-induced
member of the Hes family (Jarriault et al., 1998; Kuroda et al.,
1999). Hes6 has been shown to interact with Hes1 in in vitro
binding assays and in reporter assays, where Hes6 relieves
Hes1-mediated inhibition of an N box reporter (Bae et al.,
2000). Hes1 overexpression causes a variety of responses in
different cell lines. In differentiating PC12 cells, Hes1 parallels
the effects of Hes6 overexpression that we observe in C2C12
cells. Acting via the orange domain, Hes1 inhibits the p21Cip1
promoter when PC12 cells are induced to differentiate by nerve
growth factor (Castella et al., 2000). However, Hes1 has no
effect on cell cycle in a B cell line (Morimura et al., 2000). In
contrast to Hes6, Hes1 overexpression does not block the
differentiation of C2C12 cells, indicating that these proteins
have distinct functions in myogenesis (Shawber et al., 1996).
It is possible that some aspects of the phenotype seen in Hes6
and Hes6DBM over expressing cells are due to inhibition of
Hes1 function by Hes6. Further investigation is required to see
if additional interacting proteins are also involved.
Hes6 in Xenopus myogenesis
While C2C12 myoblasts are useful for studying late myogenic
differentiation, their committed lineage prevents the modelling
of early events. To study the role of Hes6 in both early and
late myogenesis in vivo, we have taken the complimentary
approach of overexpression in Xenopus embryos.
Analysis of the expression pattern of XHes6 revealed that it
is localised in lateral and ventral involuting mesoderm at the
gastrula stage, overlapping the expression of the myogenic
gene MyoD, consistent with a role in early myogenesis (Frank
and Harland, 1991). However, by the tailbud stage, and in
contrast to MyoD, XHes6 RNA is undetectable in anterior
differentiated muscle. This indicates that XHes6 is
downregulated in terminal differentiation, mirroring the loss of
murine Hes6 expression that occurs as the embryonic mouse
myotome differentiates into adult skeletal muscle. However,
XHes6 expression is still conspicuously expressed in the
tailbud where new muscle is being formed (Davis and
Kirschner, 2000). 
Strikingly, the phenotype produced by XHes6
overexpression is significantly tissue restricted. There is
expansion of the myotome and an increase in the number of
differentiated primary neurones, but no gross expansion of the
neural tube or hypertrophy of the epidermis (Fig. 6) (Koyano-
Nakagawa et al., 2000). This lineage-specific expansion is in
marked contrast to the phenotype produced by overexpression
of the cytoplasmic domain of Notch, which expands the
myotome, epidermis and neural tube (Coffman et al., 1993). 
The expansion of the myotome and corresponding increase
in cell number produced by XHes6 overexpression may be due
to increased recruitment of cells into the muscle lineage and/or
increased myoblast proliferation. Indeed early expansion of
MyoD and muscle actin on XHes6 overexpression indicates a
possible role in recruitment, while the repression of terminal
muscle differentiation in vivo (Fig. 8) and downregulation
p21Cip1 in myoblasts in vitro (Fig. 4) implies it may also
prolong proliferation. The increase in size and cell number in
the Xenopus myotome may result from a combination of
effects on recruitment and proliferation.
Interestingly, while XHes6 overexpression promotes the
formation of tissue-expressing markers of muscle commitment
and early differentiation, it actually inhibits the expression of
the terminal differentiation marker 12/101 in the enlarged
myotome. The observation that XHes6 is downregulated in
vivo in anterior muscle at the early tailbud stage is consistent
with a requirement for XHes6 expression to be lost before
terminal differentiation can occur. 
Our analysis of overexpression of Hes6 mutants has shown
that in Xenopus myogenesis, DNA binding by Hes6 is not
required to produce a muscle phenotype, while protein-protein
interactions mediated by the WRPW domain are essential. One
class of proteins that interact with the WRPW domain are the
homologues of Drosophila Groucho (Molenaar et al., 2000;
Paroush et al., 1994). XHes6 has also been shown to bind other
orange domain-containing proteins such as Xhairy1 and
Xhairy2a, such interactions probably being mediated by the
orange domain (Dawson et al., 1995; Koyano-Nakagawa et al.,
2000). The proteins that interact with XHes6 to produce the
phenotypes described here remain to be defined, but the lineage
restricted nature of the effects of XHes6 overexpression suggest
that its interaction partners will be expressed in developing
muscle and nerve but not other tissues.
Hes6 and somite formation
In tailbud stage embryos, XHes6 is expressed in two to three
chevrons immediately anterior to the tailbud (Fig. 5) (Koyano-
Nakagawa et al., 2000). Very similar expression in chevrons is
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seen in several genes implicated in somite segmentation, such
as ESR-4, ESR-5, Thalacine-1 and XDelta-2 (Jen et al., 1999;
Jen et al., 1997; Sparrow et al., 1998). Thus, XHes6 is
expressed in a spatial and temporal pattern suggestive of a role
in somite formation. Overexpression of XHes6 not only results
in an expansion of the myotome but also causes substantial
disruption of somite organisation; nuclei fail to align, cells fail
to rotate and intersomite boundaries fail to form. Instead the
myocytes remain in a chaotic mass. It is unlikely that the
observed defect in somitogenesis is caused solely by an
increase in the size of the myotome. Overexpression of MyoD
results in a substantial increase in myotome size, yet only mild,
if any, disruption of nuclear alignment, cell rotation and somite
boundary formation occurs (Ludolph et al., 1994) (A. E. V. and
A. P., unpublished). We favour the possibility that XHes6 may
play a role in somite formation beyond its ability to regulate
myotome size and muscle differentiation. Analysis of Hes6
mutants again indicates that DNA-binding activity is not
required to disrupt somitogenesis, but that the presence of the
WRPW domain is essential.
Somite formation in Xenopus is regulated by Notch
signalling, which controls the expression of the EoS
homologues ESR-4 and ESR-5 (Jen et al., 1999). While Hes6,
ESR-4 and ESR-5 have structural homology and are all found
expressed in similar posterior chevrons corresponding to
prospective somites, they have key functional differences.
Overexpression of ESR-5 results in a failure of somite
formation similar to that seen with XHes6, yet it does not affect
the size of the myotome or terminal muscle differentiation (Jen
et al., 1999). Additionally, XHes6 expression does not appear
to be regulated by Notch signalling, unlike that of ESR-4 and
ESR-5, which both lie within the Notch pathway (Jen et al.,
1999). As ESR-4 and ESR-5 both contain the Groucho
homologue binding motif, WRPW, but have a phenotype
distinct from Hes6, it is unlikely that the effect of Hes6 on the
myotome is mediated by titration of Groucho homologues
alone.
Hairy is a candidate effector of somitogenesis in Xenopus,
zebrafish and chick (Jen et al., 1997; Jouve et al., 2000; Takke
and Campos-Ortega, 1999). XHes6 has been shown to bind to
both Xhairy1 and Xhairy2a in vitro and in vivo (Koyano-
Nakagawa et al., 2000). Such heteromultimers may differ in
their transcriptional properties from homomultimeric Hairy
complexes, allowing Hes6 to regulate the transcriptional
activity of Hairy (Bae et al., 2000). Hes6 may also regulate the
level of Hairy expression as overexpression of XHes6 or
XHes6DBM increases transcription of Xhairy1 in Xenopus
animal caps (Koyano-Nakagawa et al., 2000). These
observations raise the possibility that Hes6 may exert its effects
on somite formation via effects on Hairy homologues; further
investigation is required to see if this is indeed the case.
Thus, we have demonstrated that Hes6 is expressed in
developing muscle and regulates the differentiation of cultured
myoblasts. In vivo overexpression of XHes6 in Xenopus has
revealed further roles in regulation of myotome size, terminal
differentiation and somitogenesis. As DNA binding by Hes6
seems not to be essential, it will be interesting to determine
which protein-protein interactions are required to mediate
these multiple, tissue-specific effects.
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